| ODEVIXIBAT | None | ||
| 0.2MG, 0.6MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). | |||
|
Yes
| |||
| BYLVAY | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **** ********** *** *** ********* ** ***** ******* | **** ********** *** *** ********* ** ***** ******** | **** ********** *** *** ********* ** ***** ******** | **** ********** *** *** ********* ** ***** ******** | ******* ************* ** ********** | **** ********** *** *** ********* ** ***** ******** | ******* ************* ** ********** | ******** *********** ******** ************ *********** (****) **** **** ********** | **** ********** *** *** ********* ** ***** ******** | ************** *********** ** ********** | ************** *********** ** ********** | ******* ************* ** ********** | **** ********** *** *** ********* ** ***** ******** | ******** *********** ******** ************ *********** (****) **** **** ********** | ************** *********** ** ********** | **** ********** *** *** ********* ** ***** ******** | *************** *** *************** *********** **** ***** **** **** ********* (****) ********** ******** *** *** ********* *************** |
| ODEVIXIBAT | None | ||
| 0.4MG, 1.2MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). | |||
|
Yes
| |||
| BYLVAY | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **** ********** *** *** ********* ** ***** ******* | **** ********** *** *** ********* ** ***** ******** | **** ********** *** *** ********* ** ***** ******** | **** ********** *** *** ********* ** ***** ******** | ******* ************* ** ********** | **** ********** *** *** ********* ** ***** ******** | ******* ************* ** ********** | ******** *********** ******** ************ *********** (****) **** **** ********** | **** ********** *** *** ********* ** ***** ******** | ************** *********** ** ********** | ************** *********** ** ********** | ******* ************* ** ********** | **** ********** *** *** ********* ** ***** ******** | ******** *********** ******** ************ *********** (****) **** **** ********** | ************** *********** ** ********** | **** ********** *** *** ********* ** ***** ******** | *************** *** *************** *********** **** ***** **** **** ********* (****) ********** ******** *** *** ********* *************** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|